Retatrutide: 10MG

£49.99

Purity: ≥ 99%

£49.99

Retatrutide: 10MG

Name: Retatrutide: 10MG
Brand: Pure Grade Labs
Price: 49.99 GBP
Availability: InStock

£49.99

Purity: ≥ 99%

£49.99

OBESITY - Multi-pathway weight loss & reduction research

HEPATIC - Liver fat reduction & NASH treatment research

GLYCAEMIC - Blood sugar control & type 2 diabetes research

ENERGY EXPENDITURE - Metabolic rate & calorie burning research

Retatrutide is a synthetic once-weekly injectable peptide developed by Eli Lilly that simultaneously activates three distinct hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GcgR). This triple receptor activation distinguishes it from tirzepatide (GIP/GLP-1 dual agonist) and semaglutide (GLP-1 monoagonist), placing it at the frontier of incretin-based therapeutic research. A fatty acid modification enables albumin binding and extends the half-life to approximately 6 days, supporting once-weekly subcutaneous dosing.

The rationale for adding glucagon receptor agonism to GIP/GLP-1 agonism centres on glucagon's role beyond glucose counterregulation. Glucagon activates receptors in hepatic and adipose tissue to increase fatty acid oxidation and energy expenditure - an effect that GLP-1 and GIP agonism alone cannot provide. The GIP and GLP-1 components simultaneously offset the blood-sugar-elevating effects of glucagon, maintaining glycaemic safety while capturing its fat-burning benefits. Phase 2 trial data published in the New England Journal of Medicine in 2023 produced results that surprised the research community: participants on the highest dose (12mg) achieved 24.2% mean weight loss at 48 weeks - approaching outcomes seen with bariatric surgery and exceeding all previously reported pharmaceutical data at that time. Phase 3 TRIUMPH trials are ongoing as of April 2026.

Triple Mechanism: Three simultaneous pathways: GIP/GLP-1 suppress appetite centrally and enhance insulin secretion; GLP-1 delays gastric emptying; glucagon receptor agonism increases hepatic fatty acid oxidation, stimulates lipolysis in adipose tissue, and elevates resting metabolic rate - creating a caloric deficit through reduced intake, slower absorption, and increased expenditure simultaneously.

Research Context: Phase 2 evidence from two published RCTs: obesity trial (n=338, 48 weeks, NEJM 2023) and T2D trial (n=281, 36 weeks, Lancet 2023). Phase 3 TRIUMPH programme currently enrolling. Not yet FDA-approved for any indication as of April 2026. Represents the most advanced triple agonist candidate with published Phase 2 human data.

Formula:C₂₉₁H₄₅₉N₇₉O₈₀

Receptor Targets: GIPR + GLP-1R + GcgR

Development Stage: Phase 3 (2026)

Compound Designation: LY3437943

Form: Lyophilised Solid

Mol. Weight: 6512.3 g/mol

CAS: 2381089-83-2

PubChem CID: 156592476

The following summaries are drawn from peer-reviewed publications. Retatrutide's published human evidence base currently consists of Phase 2 data from two RCTs. Phase 3 data is not yet available. Pure Grade Labs does not interpret these findings as evidence of clinical efficacy in humans, and notes that Phase 2 findings must be confirmed in larger Phase 3 trials.

New England Journal of Medicine: Phase 2 obesity trial: Retatrutide 12mg produces 24.2% mean weight loss at 48 weeks in adults with obesity (n=338)

The Lancet: Phase 2 T2D trial: Retatrutide produces 16.9% weight loss and HbA1c reduction of 2.2% over 36 weeks, outperforming dulaglutide (n=281)

Nature Medicine: Retatrutide reduces liver fat by up to 82% in a Phase 2 sub-study of participants with metabolic dysfunction-associated steatotic liver disease (n=98)

References

https://pubmed.ncbi.nlm.nih.gov/38367045/

https://pubmed.ncbi.nlm.nih.gov/37366315/

https://pubmed.ncbi.nlm.nih.gov/37385280/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/

https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/

https://pmc.ncbi.nlm.nih.gov/articles/PMC11420505/

https://clinicaltrials.gov/study/NCT05936151

Every batch of Retatrutide supplied by Pure Grade Labs is accompanied by a Certificate of Analysis (COA) from an independent third-party analytical laboratory. The COA confirms identity, purity by HPLC, and absence of contaminants. Batch-specific documentation is linked below.

Retatrutide is supplied as a lyophilised (freeze-dried) solid. As a complex fatty-acid-modified peptide, correct handling conditions are critical to preserving structural integrity and compound activity. Follow all specifications below.

Temperature: -20°C Long-term storage. For short-term use (up to 4 weeks), 2-8°C is acceptable.

Light Sensitivity: Light-Sensitive. Store in original opaque vial. Avoid direct UV or prolonged exposure to light.

Shelf Life: 24 Months. Lyophilized, sealed, stored at -20°C. Batch expiry printed on vial label.

Allow the sealed vial to reach room temperature before opening to avoid condensation introducing moisture to the lyophilised powder.
Use bacteriostatic water (BAC water) as the reconstitution solvent. Add solvent slowly down the inside wall of the vial - do not inject directly onto the powder.
Gently swirl the vial for 30-60 seconds until fully dissolved. Do not vortex or shake vigorously. The fatty acid modification makes this peptide sensitive to mechanical agitation.
Inspect the solution: it should be clear and colourless. Discard if cloudy, discoloured, or contains particulate matter.
Once reconstituted, store at 2-8°C. Use within 28 days. Do not freeze reconstituted solution.

Retatrutide supplied by Pure Grade Labs is intended exclusively for in vitro research and laboratory use. Retatrutide (LY3437943) is an investigational compound that has not been approved by the FDA, MHRA, EMA, TGA, or any other regulatory authority for any indication as of April 2026. Phase 3 clinical trials are ongoing.

This product is not a drug, medicine, or supplement and must not be used as such.
Pure Grade Labs makes no claims regarding therapeutic or clinical efficacy in humans. Published data derives from Phase 2 trials only - Phase 3 confirmation has not yet been achieved.
This product must not be administered to humans or animals outside of a licensed research or clinical trial context.
Retatrutide is not approved for prescription in any jurisdiction. Its regulatory status as an investigational compound means purchase and use are subject to restrictions that vary significantly by jurisdiction.
Known safety signals from Phase 2 data include gastrointestinal adverse events (nausea, vomiting, diarrhoea, constipation), which were dose-related and predominantly mild to moderate. Discontinuation due to adverse events was reported in 6-16% of participants at higher doses.
WADA classification status should be verified by athletes and their representatives before use, as classifications for investigational compounds may be updated.
Purchasers are solely responsible for compliance with all applicable laws and regulations in their jurisdiction.

All product information, research summaries, and study citations presented on this page are provided for informational context only and do not constitute medical advice, endorsement of any treatment, or recommendation for human use.